RP-102124 is a first-in-class allosteric inhibitor of multi-Rac with activity against oncogenic Rac1b. RP-102124 is orally bioavailable and exhibits dose-dependent inhibition of tumor growth in xenograft models. It exhibits potent inhibition of phenotypic characteristics of Rac signaling such as cell migration and cytoskeletal rearrangements.

RP-102124 is a first-in-class allosteric inhibitor of multi-Rac with activity against oncogenic Rac1b. RP-102124 is orally bioavailable and exhibits dose-dependent inhibition of tumor growth in xenograft models. It exhibits potent inhibition of phenotypic characteristics of Rac signaling such as cell migration and cytoskeletal rearrangements.

RP-102124 is a first-in-class allosteric inhibitor of multi-Rac with activity against oncogenic Rac1b. RP-102124 is orally bioavailable and exhibits dose-dependent inhibition of tumor growth in xenograft models. It exhibits potent inhibition of phenotypic characteristics of Rac signaling such as cell migration and cytoskeletal rearrangements.

RP-102124 is a first-in-class allosteric inhibitor of multi-Rac with activity against oncogenic Rac1b. RP-102124 is orally bioavailable and exhibits dose-dependent inhibition of tumor growth in xenograft models. It exhibits potent inhibition of phenotypic characteristics of Rac signaling such as cell migration and cytoskeletal rearrangements.

BHPI is a potent noncompetitive inhibitor of estrogen receptor α (ERα), which disrupts the protective estrogen–ERα-mediated activation of the unfolded protein response (UPR), leading to sustained UPR activation. It specifically inhibits the growth of drug-resistant ERα-positive breast and ovarian cancer cells and induces significant tumor regression in a mouse xenograft model of breast cancer.

BHPI is a potent noncompetitive inhibitor of estrogen receptor α (ERα), which disrupts the protective estrogen–ERα-mediated activation of the unfolded protein response (UPR), leading to sustained UPR activation. It specifically inhibits the growth of drug-resistant ERα-positive breast and ovarian cancer cells and induces significant tumor regression in a mouse xenograft model of breast cancer.

BHPI is a potent noncompetitive inhibitor of estrogen receptor α (ERα), which disrupts the protective estrogen–ERα-mediated activation of the unfolded protein response (UPR), leading to sustained UPR activation. It specifically inhibits the growth of drug-resistant ERα-positive breast and ovarian cancer cells and induces significant tumor regression in a mouse xenograft model of breast cancer.

BHPI is a potent noncompetitive inhibitor of estrogen receptor α (ERα), which disrupts the protective estrogen–ERα-mediated activation of the unfolded protein response (UPR), leading to sustained UPR activation. It specifically inhibits the growth of drug-resistant ERα-positive breast and ovarian cancer cells and induces significant tumor regression in a mouse xenograft model of breast cancer.

L-778123 hydrochloride is a potent dual inhibitor of farnesyl protein transferase (FPTase) with an IC50 of 2 nM and geranylgeranyl protein transferase I (GGPTase-I) with an IC50 of 98 nM. It also displays promising anti-leukemia activity.

L-778123 hydrochloride is a potent dual inhibitor of farnesyl protein transferase (FPTase) with an IC50 of 2 nM and geranylgeranyl protein transferase I (GGPTase-I) with an IC50 of 98 nM. It also displays promising anti-leukemia activity.